



# Product Manual

## **APP $\Delta$ C31 ELISA Kit**

Catalog #ADI-900-227

96-Well Enzyme Immunoassay Kit



# Product Manual

## **USE FOR RESEARCH PURPOSES ONLY**

Unless otherwise specified expressly on the packaging, all products sold hereunder are intended for and may be used for research purposes only and may not be used for food, drug, cosmetic or household use or for the diagnosis or treatment of human beings. Purchase does not include any right or license to use, develop or otherwise exploit these products commercially. Any commercial use, development or exploitation of these products or development using these products without the express written authorization of Enzo Life Sciences, Inc. is strictly prohibited. Buyer assumes all risk and liability for the use and/or results obtained by the use of the products covered by this invoice whether used singularly or in combination with other products.

## **LIMITED WARRANTY; DISCLAIMER OF WARRANTIES**

These products are offered under a limited warranty. The products are guaranteed to meet all appropriate specifications described in the package insert at the time of shipment. Enzo Life Sciences' sole obligation is to replace the product to the extent of the purchasing price. All claims must be made to Enzo Life Sciences, Inc., within five (5) days of receipt of order. THIS WARRANTY IS EXPRESSLY IN LIEU OF ANY OTHER WARRANTIES OR LIABILITIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT OF THE PATENT OR OTHER INTELLECTUAL PROPERTY RIGHTS OF OTHERS, AND ALL SUCH WARRANTIES (AND ANY OTHER WARRANTIES IMPLIED BY LAW) ARE EXPRESSLY DISCLAIMED.

## **TRADEMARKS AND PATENTS**

Several Enzo Life Sciences products and product applications are covered by US and foreign patents and patents pending.

**FOR RESEARCH USE ONLY.  
NOT FOR USE IN DIAGNOSTIC PROCEDURES.**



Reagents  
require  
separate  
storage  
conditions.



Please read  
entire booklet  
before  
proceeding  
with the  
assay.

## Table of Contents

Background.....	2
Principle .....	3
Materials Supplied .....	4
Storage .....	5
Other Materials Needed.....	5
Sample Handling.....	6
Linearity .....	7
Parallelism .....	7
Spike and Recovery.....	8
Reagent Preparation.....	9
Assay Procedure.....	10
Calculation of Results .....	11
Typical Results.....	12
Performance Characteristics.....	13
Experimental Evaluation .....	15
References.....	16
Contact Information.....	18

## BACKGROUND


Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the senile plaques, neurofibrillary tangles and loss of synapses and neurons. AD has been largely viewed as a disease of toxicity being mediated by the accumulation of the amyloid beta ( $A\beta$ ) peptide as plaques within the brain resulting in damage to brain cells from the binding of damaging metals, reactive oxygen species production and direct damage to cellular membranes. Recent research has suggested that the  $A\beta$  peptide is a multifunctional peptide with non-pathological effects<sup>1</sup> and that its association with AD is in conjunction with its roles in combination with other proteins such as the amyloid precursor protein (APP) resulting in the imbalance between the processes of memory formation and normal forgetting. It is through the interactions of the  $A\beta$  peptide with APP that the  $A\beta$  peptide itself can affect normal modulation and signaling of APP resulting in its indicated role in the pathogenesis of AD via signaling effects rather than chemical or physical effects.

There are three major APP isoforms ( $APP_{695}$ ,  $APP_{751}$  and  $APP_{770}$ ) that are formed through alternative splicing of precursor mRNA.  $APP_{770}$  represents the canonical sequence. The  $APP_{695}$  isoform is preferentially expressed in the central nervous system, while  $APP_{770}$  and  $APP_{751}$  are more highly expressed in peripheral tissues. It has been demonstrated that the full length  $APP_{695}$  can be cleaved via caspase at an intracellular site (Asp664) resulting in the release of a 31 amino acid C-terminal peptide (C31) from the remaining larger neo-APP fragment ( $APP \Delta C31$ ) with both of these entities being pro-apoptotic<sup>2</sup>. Immunohistochemical analysis of human brain tissue demonstrated that this cytoplasmic cleavage occurs 4-fold greater in patients with AD versus normal patients and that these cleavage products are localized to plaques and tangles in key areas of the brain affected by the disease<sup>3</sup>. A single genetic mutation of aspartic acid residue 664 to alanine of  $APP_{695}$  led to the complete blockage of the C-terminal cleavage *in vivo* reversing many characteristics of the AD phenotype in a transgenic mouse model<sup>4</sup>. Additionally, in cell culture it has been suggested that the neurotoxicity of  $A\beta$  is dependent on the cleavage of APP at Asp664<sup>5</sup> and the resulting  $A\beta$ -facilitated APP multimerization<sup>6</sup>.

Combined, this research describes the importance of this cleavage event and the associated proteins in the understanding of AD progression and affords a target for

therapeutic development. The APP $\Delta$ C31 ELISA kit is a complete, immunometric immunoassay kit for the quantitative determination of APP $\Delta$ C31 in cell lysate and cerebral spinal fluid samples with results in just 2 hours. The kit provides a simple and easy-to-use kit for the specific measurement of the neo-APP fragment from the APP  $\Delta$ C31 cleavage event which when combined with measurements of other AD associated proteins (A $\beta$ 40/42, sAPP $\alpha$  and tau/p-tau) could prove a useful biomarker for the diagnosis and monitoring of AD progression.

## PRINCIPLE



1. A yellow solution of polyclonal antibody developed against the neo epitope of APP  $\Delta$ C31 is added to the wells of a microtiter plate coated with a monoclonal antibody specific for the N-terminal portion of APP. Next, samples or standards are introduced to wells and the plate incubated.
2. Assay wells are washed and a blue solution of horseradish peroxidase (HRP) conjugate is added to wells and the plate incubated once again.
3. After washing, a TMB substrate solution is introduced to the plate wells where an HRP-catalyzed reaction generates a blue color during the final incubation step.
4. Stop solution is added to the wells and the resulting intensity of the yellow color is read at 450nm. The amount of signal is directly proportional to the level of APP  $\Delta$ C31 in the sample



Do not mix components from different kit lots or use reagents beyond the expiration date of the kit.



Protect substrate from prolonged exposure to light.



Stop solution is caustic. Keep tightly capped.

## MATERIALS SUPPLIED

- 1. APP  $\Delta$ C31 Assay Buffer:**  
28 mL, Product No. 80-2584  
Phosphate buffered saline containing proteins and detergents
- 2. APP  $\Delta$ C31 Standard, 50x:**  
25  $\mu$ L, Product No. 80-2588  
One vial containing 75nM of recombinant APP  $\Delta$ C31 standard
- 3. APP  $\Delta$ C31 Microtiter Plate:**  
One plate of 96 wells, Product No. 80-2585  
A clear plate of break-apart strips coated with a monoclonal antibody specific for APP
- 4. APP  $\Delta$ C31 Antibody:**  
5 mL, Product No. 80-2586  
1x yellow solution of rabbit polyclonal antibody specific for APP  $\Delta$ C31
- 5. APP  $\Delta$ C31 Conjugate:**  
10mL, Product No. 80-2587  
1x blue solution of donkey anti-rabbit IgG conjugated to horseradish peroxidase
- 6. Wash Buffer Concentrate:**  
27 mL, Product No. 80-1286  
20X Tris buffered saline containing detergents
- 7. TMB Substrate:**  
10 mL, Product No. 80-0350  
A solution of 3,3',5,5' tetramethylbenzidine (TMB) and hydrogen peroxide
- 8. Stop Solution 2:**  
10 mL, Product No. 80-0377  
A 1N solution of hydrochloric acid in water
- 9. APP  $\Delta$ C31 Assay Layout Sheet:**  
1 each, Product No. 30-0316
- 10. Plate Sealer:**  
2 each, Product No. 30-0012



Reagents  
require  
separate  
storage  
conditions.

## STORAGE

All kit components should be stored at 4°C **except the APP  $\Delta$ C31 Standard**, upon receipt. The Standards must be stored at or below -20°C. Shipping conditions may not reflect storage conditions.

## OTHER MATERIALS NEEDED

1. Deionized or distilled water
2. Precision pipets for volumes between 5  $\mu$ L and 1,000  $\mu$ L
3. Repeater pipet for dispensing 50  $\mu$ L and 100  $\mu$ L
4. Disposable polypropylene tubes for dilution of samples and standards
5. Disposable beakers or graduated cylinders for diluting buffer concentrates
6. A microplate shaker
7. Adsorbent paper for blotting
8. Microplate reader capable of reading a 450 nm
9. Software (such as AssayBlaster™ catalog number ADI-28-0002) for extrapolating sample values from optical density readings utilizing a four parameter logistic curve fit.

## SAMPLE HANDLING



If buffers other than those provided are used in the assay, the end-user must determine the appropriate dilution and assay validation.

The Enzo Life Sciences APP ΔC31 ELISA kit is compatible with human cerebrospinal fluid (CSF) samples and various cell lysates (with indications for human serum and plasma) for the determination of APP ΔC31 protein concentration. The amino acid sequences recognized by the ELISA antibodies are conserved between humans and rodents. Detection of mouse and rat APP ΔC31 is predicted.

Prior to testing, frozen samples should be completely thawed and mixed to ensure homogeneity and if necessary, clarified via centrifugation to isolate residual debris.

For testing and validation of the APP ΔC31 ELISA, cell lysis utilizing RIPA buffer with the following critical components was found to not interfere with the assay performance:

Component	Assay tolerance	
	(%)	Concentration
<b>Triton X-100</b>	≤ 1	≤ 15mM
<b>Sodium Deoxycholate</b>	≤ 0.5	≤ 8.3mM
<b>SDS</b>	≤ 0.1	≤ 3.3mM
<b>EDTA</b>	-----	≤ 10mM
<b>Protease inhibitor cocktail</b> (Roche Complete)	-----	1x



Sample handling procedures should be completed prior to reagent preparation.

**Note:** Experimentally observed concentrations of APP ΔC31 protein in cell lysates may vary due to cell culture/treatment conditions and/or alterations of the lysis procedure. Variations may be caused by, but are not limited to one or more of the following: cell type/species, frequency of media changes, concentration of chemical treatment, treatment duration, media supplements and cell confluency. Therefore, it is very important for each end user to optimize sample handling/dilution for their unique samples in order to obtain the best possible results for their experiment, and interpretation of experimental data should include considerations of these sources of variability.



## Linearity


Various biological matrices and a cell lysate were spiked with recombinant APP  $\Delta$ C31 (recAPP  $\Delta$ C31) and serially diluted in assay buffer and compared to the standard prepared in assay buffer and a serially diluted cell lysate prepared from transfected HEK cells overexpressing the human APP  $\Delta$ C31 protein. The minimum required dilution for each matrix was determined by identifying the dilution at which observed linearity began.

Dilution	CSF	Serum	Plasma	Cell lysate (HEK APP <sub>695</sub> )
Neat	96	----	----	----
1:2	97	92	88	----
1:4	100	100	100	101
1:8	109	94	105	93
1:16	106	----	89	100

Data reported are percentages of expected value at the given dilution tested.

## Parallelism

Parallelism experiments were carried out to determine if the recAPP  $\Delta$ C31 standard accurately mimicked native APP  $\Delta$ C31 in biological matrices. Human CSF, serum and plasma all spiked with the recAPP  $\Delta$ C31 standard were diluted with assay buffer and compared to the APP  $\Delta$ C31 standard curve and cell lysates from APP  $\Delta$ C31 expressing HEK cells. The parallel response indicates the standard effectively mimics the native molecule with no matrix interference at the dilutions tested.



**Spike and Recovery**

Recombinant APP  $\Delta$ C31 was spiked at multiple concentrations into lysates from cells transfected to over express the APP<sub>695</sub> protein and CSF samples. Matrix background was subtracted from the spiked values and the recovery was compared to the recovery of identical spikes in assay buffer. The average percent recovery for each matrix is indicated below.

Sample	Recommended Dilution	Recovery of Spike
Cell lysate (in RIPA buffer)	1mg/mL total protein	101.1%
Cerebrospinal Fluid	Neat	93.6%


## REAGENT PREPARATION

### 1. Wash Buffer

Prepare Wash buffer by diluting 25 mL of the supplied Wash Buffer concentrate with 475 mL of deionized water. Store the diluted wash buffer at room temperature.

### 2. Recombinant APP $\Delta$ C31 Standard

Label eight disposable 12 x 75mm (or similar) polypropylene tubes #1 through #8. Pipet 392  $\mu$ L assay buffer into tube #1 and 200  $\mu$ L assay buffer into tubes #2 through #8. Pipet 8  $\mu$ L of recombinant standard into tube 1. Vortex gently. Serially dilute 200  $\mu$ L of tube #1 standard to tubes #2 through #8 gently vortexing after each dilutional transfer.



**Do not store diluted standard.**

## ASSAY PROCEDURE



Bring all reagents to room temperature for at least 30 minutes prior to opening.



All standards and samples should be run in duplicate.



Pipet the reagents to the sides of the wells to avoid possible contamination.



Prior to the addition of the substrate, ensure there is no residual wash buffer in the wells. Remaining wash buffer may cause variation in assay results.

Refer to the Assay Layout Sheet to determine the number of wells to be used. Remove the wells not needed for the assay and return them, with the desiccant, to the mylar bag and seal. Store unused wells at 4°C.

1. Pipet 50  $\mu$ L of yellow APP  $\Delta$ C31 Antibody solution into each well, except the Blank.
2. Pipet 50  $\mu$ L of assay buffer into the S0 (0 pM standard) wells.
3. Pipet 50  $\mu$ L of APP  $\Delta$ C31 Standards #1 through #8 into the appropriate wells.
4. Pipet 50  $\mu$ L of the Samples into the appropriate wells.
5. Seal the plate. Incubate at room temperature on a plate shaker for 1 hour at ~500 rpm.
6. Empty the contents of the wells and wash by adding 300  $\mu$ L of wash solution to each well. Empty or aspirate the wells and repeat the wash 2 more times for a total of 3 washes. After the final wash, empty or aspirate the wells and firmly tap the plate on a lint free paper towel to remove any remaining wash buffer.
7. Add 100  $\mu$ L of blue APP  $\Delta$ C31 Conjugate solution to each well, except the Blank.
8. Seal the plate. Incubate at room temperature on a plate shaker for 30 minutes at ~500 rpm.
9. Wash as above (Step 5). Pipet 100  $\mu$ L of TMB Substrate Solution into each well.
10. Seal the plate. Incubate at room temperature on a plate shaker for 30 minutes at ~500 rpm.
11. Pipet 100  $\mu$ L Stop Solution to each well.
12. Zero the plate reader against the Blank wells, read the optical density at 450 nm. If the plate reader is not able to automatically subtract blank well values from each well, manually subtract the mean optical density of the Blank wells from all the readings.



Make sure to multiply sample concentrations by the dilution factor used during sample preparation.

## CALCULATION OF RESULTS

Several options are available for the calculation of the concentration of APP  $\Delta$ C31 in the samples. We recommend that the data be handled by an immunoassay software package utilizing a 4 parameter logistic (4PL) curve fitting program. Assay Blaster! Data analysis software (Prod. no. ADI-28-0002) is an easy-to-use and cost effective program that provides the options of point-to-point, 4PL and 5PL curve fitting options.

The concentration of APP  $\Delta$ C31 can be calculated as follows:

1. Calculate the average net OD for each standard and sample by subtracting the average Blank OD from the average OD for each standard and sample.

$$\text{Average Net OD} = \text{Average OD} - \text{Average Blank OD}$$

2. Plot the Net OD versus concentration of recAPP  $\Delta$ C31 for the standards. Approximate a line through the points. The concentration of APP  $\Delta$ C31 in the unknown samples can be determined by interpolation.


Samples with concentrations outside of the standard curve range will need to be re-analyzed using a different dilution.

## TYPICAL RESULTS

The results shown below are for illustrative purposes only and should not be used to calculate results from another assay.

Sample	Average Net OD	APP $\Delta$ C31 (pM)
Blank	0.002	---
S0	0.002	0
S1	3.433	1500
S2	2.032	750
S3	1.087	375
S4	0.559	187.5
S5	0.287	93.75
S6	0.142	46.88
S7	0.071	23.44
S8	0.035	11.72


recAPP  $\Delta$ C31 Standard Curve



## PERFORMANCE CHARACTERISTICS

### Specificity

To assess the specificity of the assay, cell lysates from HEK cells transfected to express either APP  $\Delta$ C31 or APP<sub>695</sub> were tested in both the ELISA and western blot (with monoclonal antibody 3E9, which recognizes both forms of APP). The western blot indicated similar amounts of the two APP forms were present in the cell lysates. The ELISA demonstrates the sensitive detection of APP  $\Delta$ C31 with no recognition of APP<sub>695</sub>.



### Sensitivity

The sensitivity, defined as 2 standard deviations from the mean signal at zero, was determined from 12 independent standard curves. The standard deviation was determined from 20 zero standard replicates. The sensitivity was found to be 0.92 pM.

**Precision**

**Intra-assay precision** was determined by assaying 20 replicates of three buffer controls containing the recAPP  $\Delta$ C31 standard in a single assay.

pM	%CV
907.1	3.92
560.9	1.61
208.7	2.02


**Inter-assay precision** was determined by measuring three buffer controls containing the recAPP  $\Delta$ C31 standard in multiple assays (n=12) over several days.

pM	%CV
907.4	6.04
556.6	8.26
213.1	3.40



## Experimental Evaluation

To demonstrate the use of the ELISA in a drug screening application, APP<sub>770</sub> transfected 7W CHO cells were treated with 5  $\mu$ M simvastatin, which has previously been shown to generate APP  $\Delta$ C31 production via stimulation of intracellular caspase cleavage<sup>7</sup>. Additionally, varying amounts (1-30  $\mu$ M) of the pan caspase inhibitor (3S)-5-(2,6-Difluorophenoxy)-3-[[[(2S)-3-methyl-1-oxo-2-[(2-quinolinylcarbonyl)amino]butyl]amino]-4-oxo-pentanoic acid (QVD-OPh) were administered to the cells in order to arrest the aforementioned cleavage and associated production of APP  $\Delta$ C31. Cell lysates produced after these treatments were analyzed by both western blot with an APP  $\Delta$ C31 specific antibody and the APP  $\Delta$ C31 ELISA. The western blot and ELISA results are in agreement showing treatment with increasing concentrations of caspase inhibitor reduces the production of APP  $\Delta$ C31.



**REFERENCES**

1. Lahiri D.K. and Maloney B. (2010) Beyond the signaling effect role of amyloid- $\beta_{42}$  on the processing of APP, and its clinical implications. *Experimental Neurology*, 225: 51-54.
2. Galvan V., Gorostiza O.F., Banwait S., Ataie M., Logvinova A.V., Sitaraman S., Carlson E., Sagi S.A., Chevalier N., Jin K., Greenberg D.A. and Bredesen D.E. (2006) Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. *Proceedings of the National Academy of Science*, 103: 7130-7135.
3. Bredesen D.E., Rao R.V. and Mehlen P. (2006) Cell death in the nervous system. *Nature*, 443: 796-802.
4. Banwait S., Galvan V., Zhang J., Gorostiza O.F., Ataie M., Huang W., Crippen D., Koo E.H. and Bredesen D.E. (2008) C-terminal cleavage of the amyloid-beta protein precursor at Asp664: a switch associated with Alzheimer's disease. *Journal of Alzheimer's Disease*, 13: 1-16.
5. Shaked G.M., Kummer M.P., Lu C.C., Galvan V., Bredesen D.E. and Koo E.H. (2006) A $\beta$  induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597-624). *FASEB Journal*, 20: 1254-1256.
6. Saganich M.J., Schroeder B.E., Galvan V., Bredesen D.E., Koo E.H. and Heinemann S.F. (2006) Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP. *Journal of Neuroscience*, 26: 13428-13436.
7. Descamps O., Zhang Q., John V. and Bredesen D.E. (2011) Induction of the C-terminal proteolytic cleavage of A $\beta$ PP by statins. *Journal of Alzheimer's Disease*, 25: 51-57.



# Product Manual

## NOTES



# Product Manual

## **Global Headquarters**

### **Enzo Life Sciences Inc.**

10 Executive Blvd  
Farmingdale, NY 11735

(p) 1-800-942-0430

(f) 1-631-694-7501

(e) [info-usa@enzolifesciences.com](mailto:info-usa@enzolifesciences.com)

### **Enzo Life Sciences (ELS) AG**

Industriestrasse 17, Postfach  
CH-4415 Lause / Switzerland

(p) +41/0 61 926 89 89

(f) +41/0 61 926 89 79

(e) [info-ch@enzolifesciences.com](mailto:info-ch@enzolifesciences.com)

For local distributors and detailed product information visit us  
online:

[www.enzolifesciences.com](http://www.enzolifesciences.com)